title: [Indications for radioimmunotherapy for patients with non-Hodgkin's lymphoma].
abstract: Radioimmunotherapy is a well-known treatment for non-Hodgkin's lymphoma. (90)yttrium (Y)-ibritumomab-tiuxetan consists of a radioisotope conjugated to a monoclonal anti-cluster of differentiation 20 antibody, which is targeted against B-lymphocytes. Initially the treatment indication was relapse of low-grade non-Hodgkin's lymphoma. However, (90)Y-ibritumomab-tiuxetan has later been used in clinical trials in the treatment of other types of non-Hodgkin's lymphoma and prior to stem cell transplantation. Based on the literature this systematic review aims to throw light on the future possibilities of radioimmunotherapy.
authors.affiliation: Medicinsk Hæmatologisk Afdeling L, Herlev Hospital, 2730 Herlev, Denmark. ulchfr01@heh.regionh.dk
authors.forename: Ulf Christian
authors.initials: UC
authors.lastname: Frølund
authors.forename: Per Boye
authors.initials: PB
authors.lastname: Hansen
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008224:Lymphoma, Follicular / Q000532:radiotherapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000532:radiotherapy; D020522:Lymphoma, Mantle-Cell / Q000532:radiotherapy; D008228:Lymphoma, Non-Hodgkin / Q000532:radiotherapy*; D009364:Neoplasm Recurrence, Local / Q000532:radiotherapy; D016499:Radioimmunotherapy / Q000009:adverse effects / Q000379:methods / Q000639:trends; D033581:Stem Cell Transplantation; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; C422802:ibritumomab tiuxetan